|
1
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
2
|
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
|
Clin Cancer Res
|
2009
|
24.11
|
|
3
|
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
|
N Engl J Med
|
2013
|
18.08
|
|
4
|
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
|
N Engl J Med
|
2015
|
14.71
|
|
5
|
High-throughput oncogene mutation profiling in human cancer.
|
Nat Genet
|
2007
|
12.68
|
|
6
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
7
|
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
|
N Engl J Med
|
2015
|
7.51
|
|
8
|
Modeling genomic diversity and tumor dependency in malignant melanoma.
|
Cancer Res
|
2008
|
5.95
|
|
9
|
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
|
Lancet Oncol
|
2012
|
5.32
|
|
10
|
Improved endpoints for cancer immunotherapy trials.
|
J Natl Cancer Inst
|
2010
|
5.23
|
|
11
|
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
|
Clin Cancer Res
|
2013
|
4.28
|
|
12
|
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
|
J Clin Oncol
|
2008
|
3.58
|
|
13
|
Hepatotoxicity with combination of vemurafenib and ipilimumab.
|
N Engl J Med
|
2013
|
3.51
|
|
14
|
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
|
Clin Cancer Res
|
2013
|
3.02
|
|
15
|
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
|
Clin Cancer Res
|
2012
|
2.68
|
|
16
|
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
|
Clin Cancer Res
|
2012
|
2.63
|
|
17
|
KIT gene mutations and copy number in melanoma subtypes.
|
Clin Cancer Res
|
2008
|
2.57
|
|
18
|
From genes to drugs: targeted strategies for melanoma.
|
Nat Rev Cancer
|
2012
|
2.46
|
|
19
|
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
|
J Clin Oncol
|
2003
|
2.36
|
|
20
|
Defining the critical hurdles in cancer immunotherapy.
|
J Transl Med
|
2011
|
2.32
|
|
21
|
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
|
Cancer
|
2014
|
2.12
|
|
22
|
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
|
Ann N Y Acad Sci
|
2013
|
2.03
|
|
23
|
Ipilimumab and its toxicities: a multidisciplinary approach.
|
Oncologist
|
2013
|
1.91
|
|
24
|
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
|
Proc Natl Acad Sci U S A
|
2006
|
1.88
|
|
25
|
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
|
Melanoma Res
|
2005
|
1.87
|
|
26
|
Modulation of T-cell activation by malignant melanoma initiating cells.
|
Cancer Res
|
2010
|
1.83
|
|
27
|
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
|
N Engl J Med
|
2015
|
1.80
|
|
28
|
Imatinib targeting of KIT-mutant oncoprotein in melanoma.
|
Clin Cancer Res
|
2008
|
1.73
|
|
29
|
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
|
Blood
|
2013
|
1.67
|
|
30
|
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
|
Cancer
|
2013
|
1.65
|
|
31
|
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
|
N Engl J Med
|
2015
|
1.64
|
|
32
|
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
|
J Proteome Res
|
2008
|
1.63
|
|
33
|
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
|
J Clin Oncol
|
2003
|
1.61
|
|
34
|
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
|
Clin Cancer Res
|
2013
|
1.53
|
|
35
|
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
|
Cancer J
|
2014
|
1.51
|
|
36
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Nat Rev Clin Oncol
|
2013
|
1.46
|
|
37
|
Melanoma, version 2.2013: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.44
|
|
38
|
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
|
Clin Cancer Res
|
2007
|
1.44
|
|
39
|
Mutation-driven drug development in melanoma.
|
Curr Opin Oncol
|
2010
|
1.43
|
|
40
|
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
|
Sci Transl Med
|
2011
|
1.37
|
|
41
|
Melanoma.
|
J Natl Compr Canc Netw
|
2009
|
1.37
|
|
42
|
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
|
Immunol Rev
|
2008
|
1.34
|
|
43
|
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.
|
Blood
|
2002
|
1.31
|
|
44
|
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
|
J Natl Cancer Inst
|
2012
|
1.28
|
|
45
|
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
|
Clin Cancer Res
|
2013
|
1.23
|
|
46
|
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
|
Cancer
|
2013
|
1.22
|
|
47
|
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
|
Proc Natl Acad Sci U S A
|
2003
|
1.14
|
|
48
|
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
|
Cancer Immunol Res
|
2013
|
1.11
|
|
49
|
Ipilimumab for patients with advanced mucosal melanoma.
|
Oncologist
|
2013
|
1.09
|
|
50
|
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
|
PLoS One
|
2012
|
1.09
|
|
51
|
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
|
Oncologist
|
2013
|
1.08
|
|
52
|
Melanoma, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.07
|
|
53
|
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
|
Cancer Immunol Res
|
2014
|
1.05
|
|
54
|
Active immunotherapy induces antibody responses that target tumor angiogenesis.
|
Cancer Res
|
2010
|
1.05
|
|
55
|
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
56
|
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
57
|
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
|
Mol Cancer Ther
|
2012
|
1.03
|
|
58
|
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
1.02
|
|
59
|
Cytotoxic T-lymphocyte-associated antigen-4.
|
Clin Cancer Res
|
2011
|
1.02
|
|
60
|
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
|
J Clin Invest
|
2015
|
0.98
|
|
61
|
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
|
PLoS One
|
2013
|
0.97
|
|
62
|
Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
|
AJR Am J Roentgenol
|
2011
|
0.96
|
|
63
|
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
|
Clin Cancer Res
|
2011
|
0.94
|
|
64
|
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
|
Clin Cancer Res
|
2005
|
0.93
|
|
65
|
Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.
|
Pigment Cell Melanoma Res
|
2015
|
0.92
|
|
66
|
MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.
|
Cancer Immun
|
2003
|
0.92
|
|
67
|
Melanoma.
|
J Natl Compr Canc Netw
|
2012
|
0.90
|
|
68
|
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.89
|
|
69
|
c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
|
Melanoma Res
|
2012
|
0.89
|
|
70
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
J Transl Med
|
2012
|
0.87
|
|
71
|
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
|
Clin Cancer Res
|
2008
|
0.87
|
|
72
|
Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.
|
Am J Surg Pathol
|
2008
|
0.86
|
|
73
|
Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.
|
Cancer Immunol Immunother
|
2011
|
0.86
|
|
74
|
The role of whole brain radiation therapy in the management of melanoma brain metastases.
|
Radiat Oncol
|
2014
|
0.86
|
|
75
|
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
|
Arch Dermatol
|
2012
|
0.85
|
|
76
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
J Immunother
|
2005
|
0.84
|
|
77
|
Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.
|
Arch Dermatol
|
2002
|
0.81
|
|
78
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
J Transl Med
|
2014
|
0.80
|
|
79
|
Advances in targeted therapy for melanoma.
|
Clin Adv Hematol Oncol
|
2010
|
0.79
|
|
80
|
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
|
Cancer Imaging
|
2014
|
0.78
|
|
81
|
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
|
Am J Surg Pathol
|
2016
|
0.77
|
|
82
|
Treatment for advanced melanoma: new drugs, new opportunities, new challenges.
|
Oncology (Williston Park)
|
2013
|
0.75
|
|
83
|
Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm.
|
N Engl J Med
|
2007
|
0.75
|